Oct 24, 2011 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Shortage of pathologists only adds to the challenges of providing high quality anatomic pathology testing services
DATELINE: Hangzhou, China—More than 1,200 Chinese pathologists and medical laboratory scientists assembled this weekend in a city marked by 1,500 years of history. The occasion was the first-ever combined meeting of the Chinese Society of Pathology and the Pathology Branch of the Chinese Medical Association.
Across the globe, pathologists and clinical laboratory professionals regularly hear about the rapid economic growth in China. This country is modernizing at an astounding rate and the evidence is easy to see in its major cities. That is certainly true here in Hanghzou, which has a population of 8.7 million people and is the anchor city for Zhejiang Province, with a population of approximately 54.4 million. It has many new buildings in its downtown and construction cranes are visible in every direction.
(more…)
Mar 3, 2010 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Clinical Pathology Laboratory Customers of Millipore Not Likely to See Many Changes
It only took a few days for Millipore Corporation (NYSE: MIL) to find a buyer willing to outbid Thermo Fisher Scientific Inc. (NYSE: TMO). Millipore agreed to be acquired by Merck KGaA (FWB: MRK) of Darmstadt, Germany. Merck will pay about $7.2 billion for Millipore, which tops a reported bid of $6 billion made by Thermo Fisher last week.
Because many clinical pathology laboratories use Millipore’s water purification systems and other products, the pending acquisition of Millipore by Merck represents more consolidation among vendors serving the clinical laboratory industry. The acquisition is expected to close during the second half of 2010.
(more…)
Feb 25, 2010 | Laboratory News, Laboratory Pathology
Both companies are important suppliers to clinical laboratories and research labs
In recent days, news surfaced that Thermo Fisher Scientific Inc. (NYSE: TMO) was offering $6 billion to acquire Millipore Corporation (NYSE:MIL). Neither company has confirmed the offer, but yesterday Millipore issued a statement that its Directors were “evaluating strategic options.”
Should Thermo Fisher acquire Millipore, or should Millipore find another buyer, it will mean the same thing: more consolidation among vendors who are major suppliers for clinical pathology laboratories. This would continue a global consolidation trend among clinical laboratory suppliers and in vitro diagnostics (IVD) manufacturers that reaches back more than a decade and a half.
(more…)
